SWOG clinical trial number
SWOG-9323 (E4592)
Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)
Closed
Phase
Published
Abbreviated Title
Laboratory/Clinical Correlative Studies in Non-Small Cell Lung Cancer: Ancillary Study to SWOG-9252 (INT-0115, E3590, RTOG-91-05, NCCTG 91-24-51)
Activated
03/01/1994
Closed
12/01/1996
Research committees
Lung Cancer
Publication Information Expand/Collapse
2001
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a lab ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postop adjuvant therapy
1999
Prognostic significance of p53 and K-RAS mutations in primary resected non-small cell lung cancer: Preliminary results from a propsective randomized trial of postoperative adjuvant therapy (intergroup trial 0115).
Other Clinical Trials
SWOG Clinical Trial Number
S2302
PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
86%
Open
Phase
SWOG Clinical Trial Number
A082002
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007
RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open